Notification of Rh(D)-Incompatible Transfusion
For patients who have received Rh(D) positive blood products.
Explains the exposure, the possibility of developing anti-D antibodies, and the importance of follow-up testing.
Allo Hope Foundation | Clinical Resources
Transfusion Medicine
Emergency blood transfusions save lives. In patients experiencing life-threatening hemorrhage, the use of Rh (D) positive low-titer group O whole blood (LTOWB) or red blood cells may be necessary when Rh(D) negative products are unavailable or would delay lifesaving resuscitation.
However, Rh(D) negative females of childbearing potential who receive Rh(D) positive blood products may develop anti-D antibodies. These antibodies can have important implications for future transfusions and pregnancies, including the risk of hemolytic disease of the fetus and newborn (HDFN).
Allo Hope Foundation works to support trauma teams, transfusion medicine specialists, and healthcare systems in reducing these risks through appropriate screening, patient notification, education, and follow-up.
Understanding the Risk
Why Follow-Up After Transfusion Matters
Alloimmunization is a potential complication of blood transfusion. Although the immediate priority during traumatic hemorrhage is saving the patient's life, the potential long-term implications of Rh(D) incompatible transfusion should not be overlooked.
Patients who develop anti-D antibodies may be at risk for HDFN in a future pregnancy with an Rh(D) positive fetus. Early identification of antibodies allows patients and their healthcare providers to plan appropriate prenatal monitoring and treatment.
Identify Exposure
Recognize Rh(D) negative females of childbearing potential who receive Rh(D) positive red blood cells or whole blood.
Arrange Screening
Establish appropriate post-transfusion antibody screening and follow-up to identify anti-D alloimmunization.
Inform Patients
Communicate the results and explain implications for future transfusions and pregnancies.
For Healthcare Professionals
Screening & Follow-Up
This resource outlines clinical considerations for screening and follow-up after Rh(D) incompatible transfusion.
Best Practice Guide: Screening and Follow-up for Transfusion-related Anti-D Alloimmunization
Includes screening recommendations, considerations regarding Rh immune globulin (RhIG), and strategies to improve recognition and follow-up of patients at risk.
View Best Practice Guide →
Patient Communication Resources
Patient Notification Letters
Patients should understand when they have received Rh(D)-incompatible blood products, why antibody screening matters, and what a positive antibody result could mean for their future care.
Notification of Anti-D Antibody Development
For patients whose follow-up antibody screening has identified anti-D antibodies.
Explains the diagnosis and the importance of sharing antibody history with future transfusion and obstetric care teams.
For healthcare institutions: These templates contain space for center-specific contact information and should be adapted to local follow-up workflows before being provided to patients.
Working Together
Connecting Transfusion Medicine and Maternal-Fetal Care
Preventing severe HDFN requires collaboration across specialties. Trauma and emergency medicine teams, blood banks, transfusion medicine specialists, and obstetric providers all have an important role in identifying and communicating transfusion- related alloimmunization.
When anti-D antibodies are identified, documenting the antibody history and ensuring patients understand its implications can help support safer future transfusions and earlier access to specialized prenatal care.
JOIN THE FIGHT
Get Involved
There are plenty of ways to get involved with The Allo Hope Foundation including sharing your story, participating in research, donations and more.
